ICU - Seastar Medical Holding Corp
NYSE * Health Care * Biotechnology
$3.75
$-0.46 (-10.93%)
About Seastar Medical Holding Corp
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
ICU Key Statistics
Market Cap
$16.81M
P/B Ratio
1.42
EPS
$-5.86
Revenue Growth
+5.3%
Employees
17
How ICU Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
#1
of 6
Size Rank
#6
of 6
Seastar Medical Holding Corp Company Information
- Headquarters
- Colorado; U.S.A
- Website
- seastarmedical.com
- Sector
- Health Care
- Industry
- Biotechnology